84176-77-2

Basic information

• Product Name: 1-benzyl-4-phenylpiperidine-4-methylamine
• Synonyms: 1-benzyl-4-phenylpiperidine-4-methylamine;4-Phenyl-1-(phenylmethyl)-4-piperidinemethanamine;Einecs 282-344-3;1-(1-benzyl-4-phenylpiperidin-4-yl)methanamine(SALTDATA: FREE);1-(1-BENZYL-4-PHENYLPIPERIDIN-4-YL)METHANAMINE;(1-Benzyl-4-phenylpiperidin-4-yl)methanamine
• CAS NO: 84176-77-2
• Molecular Formula: C₁₉H₂₄N₂
• Molecular Weight: 280.40726
• EINECS: 282-344-3
• Mol File: 84176-77-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 417.461°C at 760 mmHg
• Flash Point: 249.383°C
• Appearance: /
• Density: 1.03g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-benzyl-4-phenylpiperidine-4-methylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-4-phenylpiperidine-4-methylamine(84176-77-2)
• EPA Substance Registry System: 1-benzyl-4-phenylpiperidine-4-methylamine(84176-77-2)

Safety Data

• Hazardous Substances Data: 84176-77-2(Hazardous Substances Data)

Usage

Description

1-Benzyl-4-phenylpiperidine-4-methylamine, also known as 4-methyl-1-benzyl-4-phenylpiperidine, is a psychoactive chemical compound belonging to the class of piperidine derivatives. It is recognized for its potential stimulant and hallucinogenic effects and has been identified as a designer drug in various illicit drug formulations.

Uses

Used in Pharmaceutical Research:
1-Benzyl-4-phenylpiperidine-4-methylamine is used as a research chemical for studying its psychoactive effects and potential applications in the development of medications for neurological and psychiatric disorders. Its action as a reuptake inhibitor for neurotransmitters such as dopamine, norepinephrine, and serotonin makes it a subject of interest for research into the treatment of conditions like depression, ADHD, and Parkinson's disease.
Used in Regulatory and Control Measures:
Due to its psychoactive effects and potential for abuse, 1-benzyl-4-phenylpiperidine-4-methylamine is used as a target for regulation and control in many countries. Authorities and healthcare professionals monitor and regulate its use and distribution to mitigate the serious health risks associated with its consumption, including addiction and overdose.

InChI:InChI=1/C19H24N2/c1-3-7-17(8-4-1)15-21-16-19(11-13-20-14-12-19)18-9-5-2-6-10-18/h1-10,20-21H,11-16H2

Upstream product

• 56243-25-5 1-benzyl-4-cyano-4-phenylpiperidine 
• 40481-13-8 4-phenyl-4-cyanopiperidine 
• 98-88-4 benzoyl chloride 

Downstream Products

• 873403-55-5 (1-benzyl-4-phenyl-[4]piperidylmethyl)-urea 
• 83898-31-1 (1-benzyl-4-phenyl-[4]piperidylmethyl)-carbamic acid ethyl ester 
• 7152-05-8 N-(1-benzyl-4-phenyl-[4]piperidylmethyl)-acetamide 
• 761355-17-3 (4-phenylpiperidin-4-yl)methanamine 
• 1013329-87-7 1-((1-benzyl-4-phenylpiperidin-4-yl)methyl)-4-methylpiperazine 
• 873403-64-6 (4-phenyl-[4]piperidylmethyl)-urea 
• 266341-44-0 1-N-Benzyl-4-phenyl-4-(3-(2-methoxyphenyl)-3-oxo-2-azaprop-1-yl)piperidine 
• 847614-98-6 C₂₁H₂₃F₃N₂O 
• 1071866-00-6 1,1-dimethylethyl {[4-phenyl-1-(phenylmethyl)-4-piperidinyl]methyl}carbamate 

Relevant articles and documents

Aryl spiro compound containing formamidine as well as preparation method and application of aryl spiro compound

The invention belongs to the field of medicinal chemistry, and particularly relates to an aryl spiro compound containing formamidine as well as a preparation method and application of the aryl spiro compound. The invention relates to three aryl spiro compounds as shown in general formulas I-III and pharmaceutically acceptable salts, enantiomers, non-isomers, tautomers, solvates, polymorphic substances or prodrugs thereof. On the basis that SHP099 is used as a lead compound, a brand new compound with guanidyl at the tail end is prepared, and the problems that an existing SHP2 inhibitor is single in structural framework and the like are solved. The aryl spiro compound has the important significance of providing many modification sites and providing a basis for later structural modification. Meanwhile, the embodiment of the invention proves that the compound has an allosteric inhibition effect on SHP2 phosphatase, and a skeleton support is provided for subsequent development of an SHP2 phosphatase inhibitor.

THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS

The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease

Heterocyclic potassium channel inhibitors

The present invention relates to a class of heterocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.